1 |
한국행정연구소. (05/06 전국행정 구역별 상주)인구편람. 1판. 서울; 한국행정연구소, 2005:554-555
|
2 |
Jeremie B, Shibamolo Y, Acimovie L, Milisavljevie S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-smallcell lung cancer: a randomized study. J Clin Oncol 1996;14: 1065-1070
DOI
PUBMED
|
3 |
Dillman RO, Herdon J, Seagren SL, Ealon WL, Green MR. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215
DOI
ScienceOn
|
4 |
Hirola S, Tsujino K, Endo M, el al. Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:291-295
|
5 |
Yamada M, Kudoh S, Hirala K, Nakajima T, Yoshigawa J. Risk factors of pneumonitis following chemoradiotherapy for lung cancer. Eur J Cancer 1998;3471-75
|
6 |
Furuse K, Kubola K, Kawahara M, el al. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group. J Clin Oncol 1995;13:869-875
DOI
|
7 |
Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LA. Radiotherapy alone for medically inoperable stage I nonsmall-cell lung cancer: The Duke experience. Int J Radiat Oncol Biol Phys 1998:40:149-154
DOI
ScienceOn
|
8 |
Atagi S, Kawahara M, Tamura T, et al. Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan clinical oncology group (JCOG9812). Jpn J Clin Oncol 2005;35:195-201
DOI
ScienceOn
|
9 |
Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003;21:3201-3206
DOI
ScienceOn
|
10 |
Lonardi F, Colei M, Pavanato G, Adami F, Gioga G, Camposlrini F. Radiothearpy for non-small cell lung cancer in patients aged 75 and over: safety, effectiveness and possible impact on survival. Lung Cancer 2000;28:43-50
DOI
ScienceOn
|
11 |
Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the radiation therapy oncology group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005;63:667-671
DOI
ScienceOn
|
12 |
Jose SS, Arnaiz MD, Lucas A, et al. Radiation therapy alone in elderly with early stage non-small cell lung cancer. Lung Cancer 2006;52:149-154
DOI
ScienceOn
|
13 |
Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005:23:3112-3124
DOI
ScienceOn
|
14 |
Firal S, Pleisfer A, Byhardl RW, Gore E. Age ia independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol 2006:29:252-257
DOI
ScienceOn
|
15 |
Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the cancer and leukemia Group B and the eastern cooperative oncology group. J Clin Oncol 1999;17:4-11
DOI
|
16 |
Furuse K, Fukuoka M, Kawahara M, el al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692-2699
DOI
PUBMED
|
17 |
Singh AK, Loekell MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003;55:337-341
DOI
ScienceOn
|
18 |
Jeremic B, Shibamolo Y, Acimovie L, Djurie L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995;13:452-458
DOI
|
19 |
Sause W, Kolesar P, Taylor S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 2000;117:358-364
DOI
ScienceOn
|
20 |
Ahn SJ, Chung WK, Nah BS, et al. Outcomes after radiotherapy in inoperable patients with squamous cell lung cancer. J Korean Soc Ther Radiol Oncol 2001 ;19:216-223
과학기술학회마을
|
21 |
Lima R, Herndon JE, Kosty M, Clamon G, Green MR. Therapy choices among older patients with lung cancer: an evaluation of two trials of the cancer and leukemia group B. Cancer 2002;94:181-187
DOI
ScienceOn
|
22 |
Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999:45:1143-1149
DOI
ScienceOn
|
23 |
Tombolini V, Bonanni A, Donato V, et al. Radiotherapy alone in elderly patients with medically inoperable stage IlIA and IIIB non-small cell lung cancer. Anticancer Res 2000;20:4829-4633
PUBMED
|
24 |
Pignon T, Gregor A, Koning CS, Roussel A, Van Glabbeke M, Scalliet P. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. Radiother Oncol 1998:46:239-248
DOI
ScienceOn
|
25 |
Yancik R, Rise LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-23
DOI
|
26 |
Cheung PCF, Mackillop WJ, Dixon P, Brundage MD, Youssef YM, Zhou S. Involved-field radiotherapy alone for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000:48703-710
|
27 |
Choy H, Akerley W, Safran H, el al. Multiinstitutional phase II trial of paclitaxel, carboplatin and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998;16:3316-3322
DOI
|
28 |
Gauden SJ, Tripeony L. The curative treatment by radiation therapy alone of stage I non-small cell lung cancer in a geriatric population. Lung Cancer 2001 ;32:71 -79
PUBMED
|